TerrAscend Closes on Acquisition of High-Performing Dispensary in Maryland

The 10,000 square foot Allegany Medical Marijuana Dispensary is located in Northwest Maryland within six miles of both the West Virgina and Pennsylvania borders

The acquisition complements TerrAscend's fully operational, state-of-the-art 150,000 square foot cultivation and processing facility in Hagerstown, MD and expands the Company's retail footprint to 32 dispensaries nationwide

Adult-use was approved by Maryland voters in November 2022

TerrAscend Corp. (" TerrAscend ") (CSE: TER) (OTCQX: TRSSF), a leading North American cannabis operator, today announced the closing of its previously announced acquisition of Allegany Medical Marijuana Dispensary ("AMMD"), a medical dispensary in Cumberland Maryland.  Under the terms of the agreement (the "Transaction"), TerrAscend has acquired a 100% equity interest in AMMD for total consideration of US$10 million in cash, in addition to entering into a long-term lease with the option to purchase the real estate.

This high-performing medical dispensary, located in Northwest Maryland within six miles of both the West Virginia and Pennsylvania borders, generated net revenues in excess of $8 million in 2022. In anticipation of adult use later this year, TerrAscend expects to rebrand the 10,000 square foot dispensary as The Apothecarium, the Company's award-winning retail dispensary concept. The dispensary will carry TerrAscend's full selection of high-quality branded products, including Gage, Kind Tree, Valhalla , and Wana edibles, subject to regulatory approval.  TerrAscend's retail footprint now includes 32 dispensaries nationwide.

"Our Maryland strategy is coming together nicely," said Jason Wild , Executive Chairman of TerrAscend. "When we entered the state, we planned to significantly expand our cultivation and manufacturing capacity, in addition to vertically integrating. Since that time we have completed and operationalized our state-of-the-art 150,000 square foot facility, and have now closed on the acquisition of this high-performing medical dispensary," continued Mr. Wild. "I could not be happier with how well we are positioned for the expected launch of Maryland's adult use program."

About TerrAscend

TerrAscend is a leading North American cannabis operator with vertically integrated operations in Pennsylvania, New Jersey, Michigan and California , licensed cultivation and processing operations in Maryland and licensed production in Canada. TerrAscend operates The Apothecarium and Gage dispensary retail locations as well as scaled cultivation, processing, and manufacturing facilities in its core markets. TerrAscend's cultivation and manufacturing practices yield consistent, high-quality cannabis, providing industry-leading product selection to both the medical and legal adult-use markets. The Company owns several synergistic businesses and brands, including Gage Cannabis, The Apothecarium, Ilera Healthcare, Kind Tree, Prism, State Flower, Valhalla Confections, and Arise Bioscience Inc. For more information, visit www.terrascend.com .

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

This news release contains "forward-looking information" within the meaning of applicable securities laws. Forward-looking information contained in this press release may be identified by the use of words such as, "may", "would", "could", "will", "likely", "expect", "anticipate", "believe, "intend", "plan", "forecast", "project", "estimate", "outlook" and other similar expressions. Forward-looking information is not a guarantee of future performance and is based upon a number of estimates and assumptions of management in light of management's experience and perception of trends, current conditions and expected developments, as well as other factors relevant in the circumstances, including assumptions in respect of current and future market conditions, the current and future regulatory environment, and the availability of licenses, approvals and permits.

Forward-looking statements in this news release include, but are not limited to: statements with respect to the impact of the success of adult use in Maryland and other financial results. Actual results and developments may differ materially from those contemplated by these statements. Such forward-looking statements are based on certain assumptions regarding expected growth, results of operations, performance, industry trends and growth opportunities. While TerrAscend considers these assumptions to be reasonable, based on information currently available, they may prove to be incorrect. Readers are cautioned not to place undue reliance on forward-looking statements.

Forward-looking information is subject to a variety of risks and uncertainties that could cause actual events or results to differ materially from those projected in the forward-looking information. Such risks and uncertainties include, but are not limited to, current and future market conditions; risks related to federal, state, provincial, territorial, local and foreign government laws, rules and regulations, including federal and state laws in the United States relating to cannabis operations in the United States ; and the risk factors set out in TerrAscend's management information circular dated October 4, 2021 , and TerrAscend's most recently filed MD&A, both filed with the Canadian securities regulators and available under TerrAscend's profile on SEDAR at www.sedar.com , and in the section titled "Risk Factors" in TerrAscend's Annual Report on Form 10-K for the year ended December 31, 2021 filed with the Securities and Exchange Commission on March 17, 2022 and as amended on March 24, 2022 .

The statements in this press release are made as of the date of this release. TerrAscend disclaims any intent or obligation to update any forward-looking information, whether as a result of new information, future events or results or otherwise, other than as required by applicable securities laws.

SOURCE TerrAscend

Cision View original content to download multimedia: https://www.newswire.ca/en/releases/archive/January2023/30/c7141.html

News Provided by Canada Newswire via QuoteMedia

TER:CNX,TRSSF
The Conversation (0)
Cannabis business with marijuana leaves and stock

Cannabis Market 2025 Year-End Review

2025 marked a turning point for investment in the cannabis sector, shifting the focus toward operational resilience and consolidation after a sluggish 2024. Key market drivers included an upswing in merger and acquisition (M&A) activity as stronger multi-state operators (MSOs) acquired... Keep Reading...
Cannabis plant with green leaves and buds on a dark green background.

Cannabis Market Forecast: Top Trends for Cannabis in 2026

The US cannabis market is entering 2026 with brighter prospects after a punishing few years marked by stalled rescheduling efforts, price compression, retail saturation and slow state expansion.Now, however, regulatory tailwinds seeming aligned for a potential re-rating.On December 18, US... Keep Reading...
Cannabis plant in focus, blurred US flag background.

Analysts React: Trump Signs Executive Order to Reschedule Cannabis

The long-debated issue of US cannabis rescheduling is finally back in the spotlight. On Thursday (December 18), President Donald Trump signed an executive order to expedite the process of moving cannabis from Schedule I to Schedule III under the Controlled Substances Act. Market watchers are now... Keep Reading...
Close-up of green cannabis leaves in natural light.

Trump Weighs Executive Order to Loosen Federal Cannabis Restrictions

US President Donald Trump is reportedly weighing a major shift in federal drug policy that would relax decades-old restrictions on cannabis, potentially injecting new life into the industry. Six people familiar with the discussions told the Washington Post that Trump is preparing an executive... Keep Reading...
Gavel on a surface with scattered cannabis leaves, symbolizing legal issues around marijuana.

Hemp THC Recriminalization: A Blow to a Blooming Industry

A spending bill to reopen the US government after a 43 day shutdown includes provisions that will recriminalize most hemp-derived THC products. This change, slated to become effective one year after enactment, in late 2026, marks a significant policy reversal from the 2018 Farm Bill, which... Keep Reading...
Cannabis buds on a wooden surface with Australian banknotes nearby.

Australia's Cannabis Import Quota Slashed Amid Surging Local Production

Australia’s Office of Drug Control (ODC) said the country’s 2025 cannabis import quota has been reduced by the International Narcotics Control Board from 101 tonnes to 88 tonnes, Business of Cannabis reported.Over-projected demand and idle permits that limited operational flexibility were cited... Keep Reading...

Interactive Chart

Latest Press Releases

Related News